Three CGT Companies Secure Funding to Advance NK Cell, CAR-T, and Gene-Regulatory Therapies

Jul 18, 2025 11:04 CST Updated 11:04

NK CellTech

Immune Cell Therapy Developer

Tcelltech

Developer of Immuno-oncology and Cell Therapy Drugs

CoRegen

Cancer Therapy Researcher

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

From July 2025 to present, according to incomplete statistics, 3 CGT pharmaceutical companies have completed financing.

1、Enkai Saiyao:Nearly 100 Million A+++ Round Financing

In July, Enkaicell announced the completionNearly 100 Million A+++ Round FinancingThis round of financing was participated by Pudong Venture Capital and Starlight Biotechnology. The funds raised in this round will be used to advance the clinical trials of core products and the development of new product pipelines, accelerating the clinical transformation of NK cell drugs.

Enkaicell, established by the core technical team led by Professor Tian Zhigang from the University of Science and Technology of China, focuses on the research, development, and production of innovative cell-based drug technologies based on NK cells. It is committed to providing patients with more effective and safer precision immunotherapy solutions. In March 2020, with the strong support of the Shanghai Municipal Government, Zhangjiang Administrative Committee, and Zhangjiang Group, Enkaicell settled in the Zhangjiang Cell Industrial Park. By 2024, two of Enkaicell's NK cell products have successively received clinical trial (IND) approval from the U.S. FDA and China's CDE.

R&D Pipeline

2. Tuoxin Tiancheng:Recently4000Million USDBRound of Financing

7Month15Day, Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. (Drimmunity / Tcelltech) AnnounceCompleteSuccessRecently4000Million USDBRound Financing. This round of financing was led by SDIC Capital,A well-known insurance capital and Hetang Venture Capital followed the investment.`, and has received strong support from institutions such as Xingye Guoxin Asset Management and Fuzhou Mindu Talent Fund.`

This round of fundraising will be mainly used to support the company's core pipeline.Cell Therapy DrugsTX-103Sino-US Clinical Development, the development of other pipeline projects, global team expansionExpand, andAccelerate the company's international strategic layout and advancementBDCooperation。

TX-103Is the world's first product to enter the registration clinical trial and conduct international clinical trials.B7-H3 CAR-TCell therapy product for recurrent glioblastoma (rGBM) and other solid tumors。

3、CoRegen: Completed $93.39 Million Financing

On July 9, clinical-stage gene therapy biotechnology company CoRegen announced the completion of a $93.39 million financing round.This financing was conducted through private placement to a small number of investors.

This round of financing will be used to advance CoRegen's Chemistry, Manufacturing, and Control (CMC) development and initiate a Phase 1/2 clinical trial for its Steroid Receptor Coactivator-3 (SRC-3) Knockout Regulatory T-cell (Treg) (SRC3-KO) project in the first half of 2026, targeting patients with various solid tumors. Additionally, key personnel will be recruited (including Chief Financial Officer, Chief Marketing Officer, and other research and regulatory positions) to expand its leadership team, drive project execution, and support the company’s growth.

This round of financing builds on the $28 million CoRegen raised earlier in 2024, which was used to support its acquisition of an exclusive license from Baylor College of Medicine to sponsor the development of its innovative gene regulation platform.

Conclusion

Overall, the financing obtained by these three companies in July not only provided strong financial support for their respective R&D and clinical translation in areas such as NK cell drugs, CAR-T cell therapy products, and gene regulation platform-related therapies, but also indirectly reflected the high level of attention and confidence from the capital market towards cell therapy and gene treatment fields.

References: Publicly Available Information

-END-

Scan to register